Breast Cancer Research Awards by Gilead Sciences Belux – Deadline submission 11 December 2023
APPLICATION PROCESS At Gilead, we’re committed to creating a healthier world for everyone. For more than 30 years, we’ve pursued …
Dear BSMO members and colleagues,
We have the pleasure to invite you for participation in part II of our nationwide, BSMO-sponsored study: ‘Characteristics and outcomes of patients with cancer and COVID-19 in Belgium’.
As you might be aware, data collection for part I of this project, where we compared in-hospital mortality between patients with and without cancer hospitalized with COVID-19 in Belgium, was achieved through collaboration with Sciensano and based on the Sciensano questionnaires, which are available for more than 70% of all hospitalized patients. Almost 1200 patients with solid cancer were evaluable for the baseline analysis in part I of this project. The manuscript has been published in ESMO Open and can be viewed here.
The Sciensano questionnaire contains information on demographics, comorbidities, COVID-19 diagnosis, treatment and outcome. However, no details on cancer status, cancer type or current/prior anticancer treatments are available in the Sciensano database. Moreover, no follow-up information is collected, which is needed to gain insights in the impact of prior hospitalization with COVID-19 on anticancer treatment plans. Therefore, additional data collection through part II is essential to clearly disentangle the correlations between COVID-19, cancer status, treatment and outcome. We need your help to ensure the success of this data collection.
So far, 24 Belgian hospitals are participating in this academic nationwide collaborative study with BSMO as legal sponsor. We have obtained funding for this study, and a financial contribution of 150€ per patient entered in this study is foreseen for the participating site.
If you are interested to participate with your institution, please send an email to Marjolein.Heijlen@uzleuven.be and we will guide you through each of the steps detailed below. Guidance given by the principal investigators of this study and a data manager dedicated to this project will be foreseen for every necessary step.
With kind regards and many thanks in advance.
On behalf of the BSMO Executive Board
Evandro de Azambuja Principal Investigator & Past BSMO Board Member Evandro.azambuja@bordet.be |
Kevin Punie Co-Principal Investigator & BSMO Board Member Kevin.punie@uzleuven.be |
Mariana Brandão Junior Principal Investigator Mariana.brandao@bordet.be |
Tatjana Geukens Junior Principal Investigator Tatjana.Geukens@uzleuven.be |
Marjolein Heijlen Study Coordinator Marjolein.heijlen@uzleuven.be |
APPLICATION PROCESS At Gilead, we’re committed to creating a healthier world for everyone. For more than 30 years, we’ve pursued …
NEW in 2023, the Pfizer Oncology Award is intended to support, recognise and encourage two innovative projects in Belgium or Luxembourg that improve …
Find our latest news here. Archive previous editions: June 2023 May 2023 April 2023 March 2023